Table 3.

Comparison of combination trials and non-combination trials in oncology and non-oncology

	Non-Oncology Combination	Oncology Combination	Oncology Non-Combination
Funded By(a)	n=4480	n=3753	n=10899
Industry	3086 (68.9%)	1839 (49.0%)	3946 (36.2%)
NIH	230 (5.1%)	853 (22.7%)	1205 (11.1%)
Other	1654 (36.9%)	2318 (61.8%)	8195 (75.2%)
U.S. Fed	39 (0.9%)	14 (0.4%)	90 (0.8%)
Primary Purpose	n=4217	n=3732	n=10545
Basic Science	236 (5.6%)	13 (0.3%)	148 (1.4%)
Diagnostic	44 (1.0%)	12 (0.3%)	858 (8.1%)
Health Services Research	9 (0.2%)	1 (0.03%)	97 (0.9%)
Prevention	458 (10.9%)	34 (0.9%)	508 (4.8%)
Screening	6 (0.1%)	3 (0.08%)	145 (1.4%)
Supportive Care	43 (1.0%)	30 (0.8%)	597 (5.7%)
Treatment	3421 (81.1%)	3639 (97.5%)	8192 (77.7%)
Endpoint Measures	n=4179	n=3311	n=9202
Bio-availability Study	63 (1.5%)	4 (0.1%)	24 (0.3%)
Bio-equivalence Study	95 (2.3%)	0 (0%)	52 (0.6%)
Efficacy Study	809 (19.4%)	795 (24.0%)	3051 (33.2%)
Pharmacodynamics	78 (1.9%)	7 (0.2%)	86 (0.9%)
Pharmacokinetics	425 (10.2%)	24 (0.7%)	103 (1.1%)
Pharmacokinetics/Dynamics	137 (3.3%)	12 (0.4%)	71 (0.8%)
Safety Study	437 (10.7%)	492 (14.9%)	947 (10.3%)
Safety/Efficacy Study	2135 (51.1%)	1977 (59.7%)	4868 (52.9%)
Allocation	n=4176	n=2413	n=6142
Non-Randomized	563 (13.5%)	795 (33.0%)	2189 (35.6%)
Randomized	3613 (86.5%)	1618 (67.0%)	3953 (64.4%)
Phase	n=4134	n=3634	n=8530
Phase 0	12 (0.3%)	15 (0.4%)	180 (2.1%)
Phase 1	1114 (27.0%)	778 (21.4%)	1657 (19.4%)
Phase 1/Phase 2	133 (3.2%)	582 (16.0%)	896 (10.5%)
Phase 2	851 (20.6%)	1655 (45.5%)	3950 (46.3%)
Phase 2/Phase 3	88 (2.1%)	52 (1.4%)	201 (2.4%)
Phase 3	1136 (27.5%)	499 (13.7%)	1183 (13.9%)
Phase 4	800 (19.4%)	53 (1.5%)	463 (5.4%)

^(a)The sum of percentages exceed 100 because trials may be funded by more than agencies